Literature DB >> 20659087

Differential role of naïve and memory CD4 T-cell subsets in primary alloresponses.

D Golshayan1, J-C Wyss, M Buckland, M Hernandez-Fuentes, R I Lechler.   

Abstract

The T cell response to major histocompatibility complex (MHC) alloantigens occurs via two main pathways. The direct pathway involves the recognition of intact allogeneic MHC:peptide complexes on donor cells and provokes uniquely high frequencies of responsive T cells. The indirect response results from alloantigens being processed like any other protein antigen and presented as peptide by autologous antigen-presenting cells. The frequencies of T cells with indirect allospecificity are orders of magnitude lower and comparable to other peptide-specific responses. In this study, we explored the contributions of naïve and memory CD4(+) T cells to these two pathways. Using an adoptive transfer and skin transplantation model we found that naive and memory CD4(+) T cells, both naturally occurring and induced by sensitization with multiple third-party alloantigens, contributed equally to graft rejection when only the direct pathway was operative. In contrast, the indirect response was predominantly mediated by the naïve subset. Elimination of regulatory CD4(+)CD25(+) T cells enabled memory cells to reject grafts through the indirect pathway, but at a much slower tempo than for naïve cells. These findings have implications for better targeting of immunosuppression to inhibit immediate and later forms of alloimmunity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20659087     DOI: 10.1111/j.1600-6143.2010.03180.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  9 in total

Review 1.  Alloimmune T cells in transplantation.

Authors:  Susan DeWolf; Megan Sykes
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

Review 2.  Bacterial infections, alloimmunity, and transplantation tolerance.

Authors:  Emily B Ahmed; Melvin Daniels; Maria-Luisa Alegre; Anita S Chong
Journal:  Transplant Rev (Orlando)       Date:  2011-01       Impact factor: 3.943

3.  The suppressive effect on CD4 T cell alloresponse against endothelial HLA-DR via PD-L1 induced by anti-A/B ligation.

Authors:  K Iwasaki; H Hamana; H Kishi; T Yamamoto; T Hiramitsu; M Okad; T Tomosugi; A Takeda; S Narumi; Y Watarai; Y Miwa; M Okumura; Y Matsuoka; K Horimi; A Muraguchi; T Kobayash
Journal:  Clin Exp Immunol       Date:  2020-07-18       Impact factor: 4.330

Review 4.  Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation.

Authors:  Ilse Gille; Frans H J Claas; Geert W Haasnoot; Mirjam H M Heemskerk; Sebastiaan Heidt
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

Review 5.  TCR cross-reactivity and allorecognition: new insights into the immunogenetics of allorecognition.

Authors:  L J D'Orsogna; D L Roelen; I I N Doxiadis; F H J Claas
Journal:  Immunogenetics       Date:  2011-12-03       Impact factor: 2.846

Review 6.  Analysis of T-Cell Receptor Repertoire in Transplantation: Fingerprint of T Cell-mediated Alloresponse.

Authors:  Guangyao Tian; Mingqian Li; Guoyue Lv
Journal:  Front Immunol       Date:  2022-01-12       Impact factor: 7.561

Review 7.  Heterologous Immunity of Virus-Specific T Cells Leading to Alloreactivity: Possible Implications for Solid Organ Transplantation.

Authors:  Gonca E Karahan; Frans H J Claas; Sebastiaan Heidt
Journal:  Viruses       Date:  2021-11-24       Impact factor: 5.048

Review 8.  High Throughput Human T Cell Receptor Sequencing: A New Window Into Repertoire Establishment and Alloreactivity.

Authors:  Jianing Fu; Mohsen Khosravi-Maharlooei; Megan Sykes
Journal:  Front Immunol       Date:  2021-11-05       Impact factor: 7.561

9.  Differential activation of human T cells to allogeneic endothelial cells, epithelial cells and fibroblasts in vitro.

Authors:  Dmitry Samsonov; Christopher Geehan; Craig B Woda; David M Briscoe
Journal:  Transplant Res       Date:  2012-04-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.